分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Mesenchymal stem cells receive adaptive islet–derived miR-151–containing sEVs to promote β cell compensation in obesity

Xinwei Guo, Yang Wang, Ruixue Du, Wei Yong, Wenjing Yan, Zicheng Zhang, Yi Pan, Yanfeng Zhang, Yumeng Shen, Yue Yang, Fangfang Zhang, Jianxing Liu, Wei Tang, Yue Liu, Liang Jin

Journal:Science Advances

IF:13.9

DOI:10.1126/sciadv.adu4196

PMID:

Published:2026-07-17

research field:分子生物学风湿病学细胞治疗免疫学干细胞研究炎症自身免疫性疾病

Abstract

Pancreatic islets respond to obesity-related insulin resistance by increasing β cell mass and insulin secretion. However, the molecular mechanisms behind this vital compensation are not fully understood. This study shows that adaptive islet–derived small extracellular vesicles (aid-sEVs) play a key role in β cell adaptation in obesity. Aid-sEV production rises under hyperlipidemic conditions, and uptake by adjacent cells occurs via F11R-mediated recognition. Mesenchymal stem cells (MSCs) act as downstream effectors after they internalize aid-sEVs, promoting β cell–adaptive responses. These vesicles deliver miR-151 to MSCs, triggering miR-151– dependent cellular reprogramming toward a Wnt-secreting phenotype. Restoration of miR-151 in microRNA-deficient aid-sEVs restores their proadaptive effects on β cells. Klf9 , a direct target of miR-151 , is involved in regulating MSC proliferation and WNT secretion by controlling Wnt3a and Ccnd1 transcription. These findings reveal a critical pathway controlling β cell compensation in diet-induced obesity and indicate that targeted enhancement of aid-sEV secretion could be a therapeutic strategy to counteract β cell dysfunction in diabetic patients.

本文使用的Yeasen产品

购物车
客服
转染试用